secwatch.observer — SEC 8-K summary
======================================

Issuer:     Theriva Biologics, Inc. (TOVX)
CIK:        0000894158
Form:       8-K
Filed at:   2024-09-16T23:59:59+00:00
Accession:  0001104659-24-100010
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 2.03, 8.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Theriva Biologics awarded €2.28M Spanish government funding for THERICEL cell platform
--------------------------------------------------------------------------------

- €1.33M unsecured loan lump sum in Q4 2024; interest 4.015%; repayable over 7 yrs after 3-yr grace.
- €0.95M grant to Universitat Autònoma de Barcelona paid in annual installments over 3 years.
- Funds to advance suspension cell platform for adenovirus/AAV therapies; scaling VCN-01 production.
- Award validates proprietary A549 suspension cell platform for clinical manufacturing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/894158/000110465924100010/0001104659-24-100010-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/894158/000110465924100010/tm2424064d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-100010

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer